PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MXICO
Oct 1, 2009, 00:00
10.1016/S1098-3015(10)75341-9
https://www.valueinhealthjournal.com/article/S1098-3015(10)75341-9/fulltext
Title :
PCN14 THE COST AND COST EFFECTIVENESS OF DASATINIB (SPRYCEL) 100 MG THERAPY FOR THE MANAGEMENT OF IMATINIB RESISTANT AND INTOLERANT PATIENTS IN CHRONIC PHASE WITH CHRONIC MYELOID LEUKEMIA (CML) IN MXICO
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)75341-9&doi=10.1016/S1098-3015(10)75341-9
First page :
Section Title :
Open access? :
No
Section Order :
1269